Expertise in
9
conditions

Dr. David Goddard

Rheumatology
Cobble Hill Gynecology FPP
186 Joralemon St, 
Brooklyn, NY 
Offers Telehealth
Expertise in
9
conditions
Cobble Hill Gynecology FPP
186 Joralemon St, 
Brooklyn, NY 

Overview

David Goddard is a Rheumatologist in Brooklyn, New York. Dr. Goddard is highly rated in 9 conditions, according to our data. His top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Juvenile Temporal Arteritis, and Temporal Arteritis.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in NY

Hospital Affiliations

Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cobble Hill Gynecology FPP
186 Joralemon St, Brooklyn, NY 11201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: June 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

1 Total Publications

A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases.
A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases.
Journal: ACR open rheumatology
Published: July 22, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (1.9 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology
Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (1.0 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances

Alice Gottlieb is a Rheumatologist in New York, New York. Dr. Gottlieb is highly rated in 35 conditions, according to our data. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Generalized Pustular Psoriasis (GPP), and Hidradenitis Suppurativa.

Expertise in
20
conditions
Dr. Lindsay Lally
Rheumatology
Expertise in
20
conditions
Dr. Lindsay Lally
Rheumatology

Belaire Building

525 E 71st St Fl 7, 
New York, NY 
 (2.0 miles away)
212-774-2434
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lindsay Lally is a Rheumatologist in New York, New York. Dr. Lally has been practicing medicine for over 18 years is highly rated in 20 conditions, according to our data. Her top areas of expertise are Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, Temporal Arteritis, and Giant Cell Arteritis (GCA).

Frequently Asked Questions about Dr. David Goddard

How do I make an appointment with Dr. David Goddard?

You can book an appointment with Dr. David Goddard by calling their office at 929-455-2399. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Goddard a top-rated expert for Postmenopausal Osteoporosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Goddard is classified as an Advanced expert for Postmenopausal Osteoporosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Goddard specialize in?

While Dr. David Goddard is a Rheumatology, they have specific expertise in Postmenopausal Osteoporosis, Osteoporosis, and Juvenile Temporal Arteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. David Goddard participate in research or clinical trials?

Yes. Dr. David Goddard has published 1 articles and abstracts on conditions like Postmenopausal Osteoporosis. You can view a list of Dr. David Goddard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Goddard accept my insurance?

Dr. David Goddard accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 929-455-2399 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goddard's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile